CPHA Canvax
CPHA Canvax

"In preauthorization trials for Pfizer-BioNTech (BNT162b2) COVID-19 vaccine, vaccinated children aged 5–11 years reported mild to moderately severe local and systemic reactions; no serious vaccination-related events were noted. 

After authorization of Pfizer-BioNTech COVID-19 vaccine for children aged 5–11 years during October 2021, and administration of approximately 8 million doses, local and systemic reactions after vaccination were commonly reported to VAERS and v-safe for vaccinated children aged 5–11 years. Serious adverse events were rarely reported.

Parents and guardians of children aged 5–11 years should be advised that local and systemic reactions are expected after vaccination with Pfizer-BioNTech COVID-19 vaccine and are more common after the second dose." - COVID-19 Vaccine Safety in Children Aged 5–11 Years — United States, November 3–December 19, 2021

Additional Authors: John R. Su, Bicheng Zhang, Deborah Thompson, Tom T. Shimabukuro, David K. Shay


Related Resources





Vaccine Safety and Development,Vaccine Safety,Vaccine Safety,Adverse Events Following Immunization (AEFI),Vaccine Monitoring and Surveillance,Outbreaks and Pandemics,COVID-19,Specific Populations,Children,School-aged Vaccine Safety and Development
Vaccine Safety
Vaccine Safety
Adverse Events Following Immunization (AEFI)
Vaccine Monitoring and Surveillance
Outbreaks and Pandemics
Specific Populations


Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.

All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.